Literature DB >> 28378546

Clinical and Epidemiologic Characteristics of Spreaders of Middle East Respiratory Syndrome Coronavirus during the 2015 Outbreak in Korea.

Chang Kyung Kang1, Kyoung Ho Song1, Pyoeng Gyun Choe1, Wan Beom Park1, Ji Hwan Bang1, Eu Suk Kim1, Sang Won Park1, Hong Bin Kim1, Nam Joong Kim1, Sung Il Cho2,3, Jong Koo Lee2,3, Myoung Don Oh1,4.   

Abstract

Nosocomial transmission is an important characteristic of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. Risk factors for transmission of MERS-CoV in healthcare settings are not well defined. During the Korean outbreak in 2015, 186 patients had laboratory-confirmed MERS-CoV infection. Those suspected as a source of viral transmission were categorized into the spreader groups (super-spreader [n = 5] and usual-spreader [n = 10]) and compared to the non-spreader group (n = 171). Body temperature of ≥ 38.5°C (adjusted odds ratio [aOR], 5.54; 95% confidence interval [CI], 1.38-22.30; P = 0.016), pulmonary infiltration of ≥ 3 lung zones (aOR, 7.33; 95% CI, 1.93-27.79; P = 0.003), and a more nonisolated in-hospital days (aOR, 1.32 per 1 day; 95% CI, 1.09-1.60; P = 0.004) were significant risk factors in the spreader group. There was no different clinical factor between super-spreaders and usual-spreaders. Nonisolated in-hospital days was the only factor which tended to be higher in super-spreaders than usual-spreaders (Mean, 6.6 vs. 2.9 days; P = 0.061). Early active quarantine might help reducing the size of an outbreak.
© 2017 The Korean Academy of Medical Sciences.

Entities:  

Keywords:  Hospital Infection; Infection Transmission; Korea; MERS-CoV; Outbreak

Mesh:

Year:  2017        PMID: 28378546      PMCID: PMC5383605          DOI: 10.3346/jkms.2017.32.5.744

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


INTRODUCTION

Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel beta-coronavirus first identified in Saudi Arabia in 2012 (1). It causes severe acute respiratory infection, with a mortality rate of 36% (2). Most MERS-CoV infections occur in the Middle East, although travel-associated MERS cases have been reported in 17 countries outside the Middle East. As of November 3, 2016, 27 countries reported 1,813 laboratory-confirmed cases of infection with MERS-CoV, including 645 deaths, to the World Health Organization (WHO) (2). In the Korean outbreak of MERS-CoV in 2015, the first known patient was a businessman returning from the Middle East. The outbreak was amplified by super-spreading events at hospitals and movement of patients between hospitals. Spreading events occurred until late June 2015, more than a month after the index patient was identified, resulting in a total of 186 patients with MERS-CoV infection and 38 fatalities, which is the largest outbreak outside the Arabian Peninsula (34). During the outbreak, almost 17,000 individuals at epidemiologic risk were quarantined, and all laboratory-confirmed cases were admitted to hospitals for isolation. Of MERS-CoV cases, 44%–100% of individual outbreaks were linked to hospitals (56) and a nosocomial outbreak of MERS-CoV may result in a large cluster of cases, the so called “super-spreading events (67).” However, it is not known whether the spreading events are attributable to host factors such as clinical manifestations or epidemiologic factors such as duration of the nonisolated period (8). To understand the transmission risk of MERS-CoV in healthcare settings, we assessed the clinical and epidemiologic characteristics of non-spreaders, spreaders, and super-spreaders during the Korean outbreak.

MATERIALS AND METHODS

Patients and data collection

All laboratory-confirmed cases were admitted to government-designated hospitals, regardless of the severity of their illness. They were discharged after the resolution of all clinical symptoms and when 2 consecutive daily sputum samples were negative for MERS-CoV by real-time reverse transcription polymerase chain reaction (rRT-PCR). Laboratory diagnoses were made according to the WHO guideline (9). We reviewed the publically available epidemiologic database compiled by the Korea Centers for Disease Control and Prevention (3) and clinical database compiled by the Korean Society of Infectious Diseases (KSID) (10). Infectious disease specialists who had cared for MERS patients completed case record form which KSID developed. The clinical data included demographics, clinical features, and the results of the laboratory tests. Government daily reports and local Korean news reports on the MERS outbreak were also reviewed (11).

Definitions and subgroup analyses

A spreader was defined as an index patient who was suspected of causing a secondary infection of MERS-CoV. Super-spreaders and usual-spreaders were defined as those who transmitted MERS-CoV to 6 or more and those who transmitted to fewer than 6 individuals, respectively. Nonisolated in-hospital days were defined as the sum of calendar days of the patient's hospital stay before being effectively isolated. Chest radiographs at presentation were analyzed and the number of abnormal lung zones, which were arbitrarily divided into 6 areas, was counted. For subgroup analyses, we censored cases with symptom onset after June 7 after which stricter infection control measures were implemented by the government, such as public disclosure of the names of affected hospitals, organizing rapid response teams, and applying stronger surveillance and isolation policies (12). Healthcare workers were also censored in another subgroup analyses because many wore personal protective equipment, which could also confound the transmission risk.

Statistical analysis

Multivariate analyses in a forward stepwise manner were performed with P = 0.050 as the threshold for entering and removing variables. For all analyses, a 2-tailed P value of 0.05 was considered significant. Statistical analyses were performed with PASW for Windows (version 18 software package; SPSS, Inc., Chicago, IL, USA).

Ethics statement

The Institutional Review Board at the Seoul National University Hospital approved the study. The board waived the requirement for written consent (IRB registration number 1607-062-775).

RESULTS

Baseline characteristics

Characteristics of 186 patients with laboratory-confirmed MERS-CoV infection are shown in Table 1. Of them, 15 patients (8.1%) transmitted MERS-CoV (the spreader group) to others, and 171 patients (91.9%) did not (the non-spreader group). Age, sex, and underlying diseases were not different between the 2 groups. Among the spreaders, 5 patients (33.3%) were super-spreaders, while 10 (66.7%) were usual-spreaders. Baseline characteristics of these 2 groups were not significantly different.
Table 1

Comparison of patient demographics and clinical parameters between non-spreaders and spreaders, or usual-spreaders and super-spreaders during the 2015 Korean outbreak of MERS-CoV

CharacteristicsNon-spreader (n = 171)Spreader (n = 15)P value
Usual-spreader (n = 10)Super-spreader (n = 5)Non-spreader vs. spreaderUsual-spreader vs. super-spreader
Patient characteristics
 Age, mean (± SD)54.4 (± 16.2)54.4 (± 18.0)50.6 (± 19.3)0.7800.689
 Male99 (57.9)8 (80.0)4 (80.0)0.1081.000
 Underlying diseases
  DM33 (19.3)0 (0.0)1 (20.0)0.2511.000
  Hypertension51 (29.8)3 (30.0)1 (20.0)0.7970.682
  Chronic kidney diseases8 (4.7)1 (10.0)0 (0.0)0.7321.000
  Chronic heart diseases15 (8.8)0 (0.0)0 (0.0)0.999NA
  Chronic lung diseases17 (9.9)2 (20.0)0 (0.0)0.6790.999
  Chronic liver diseases9 (5.3)1 (10.0)0 (0.0)0.8181.000
Clinical characteristics at presentation
 Signs and symptoms*
  Fever (≥ 38.5℃)22 (13.0)5 (50.0)1 (20.0)0.0090.280
  Systolic BP ≤ 90 mmHg9 (5.3)2 (20.0)0 (0.0)0.2270.999
  Diastolic BP ≤ 60 mmHg28 (16.6)3 (30.0)1 (20.0)0.3290.682
  Respiratory rate > 24/min21 (12.4)5 (50.0)0 (0.0)0.0340.999
  Cough93 (55.0)9 (90.0)4 (80.0)0.0310.598
  Sputum63 (37.3)9 (90.0)2 (40.0)0.0110.062
  Dyspnea32 (18.9)6 (60.0)3 (60.0)0.0011.000
  Myalgia71 (42.0)5 (50.0)3 (60.0)0.3990.715
  Headache34 (20.1)1 (10.0)2 (40.0)0.9910.199
  Diarrhea32 (18.9)1 (10.0)2 (40.0)0.9200.199
 Laboratory tests
  WBC > 10,000 /μL or < 4,000 /μL75 (46.6)4 (40.0)4 (80.0)0.6170.165
  Platelet < 100,000 /μL28 (17.4)3 (30.0)2 (40.0)0.1400.699
  CRP ≥ 3.0 mg/dL66 (43.4)8 (88.9)4 (80.0)0.0080.653
  BUN > 20 mg/dL§24 (15.4)4 (40.0)0 (0.0)0.2670.999
  Creatinine > 1.5 mg/dL§8 (5.1)1 (10.0)0 (0.0)0.7991.000
 CXR abnormality in more than 3 lung zones17 (10.3)5 (50.0)2 (40.0)< 0.0010.715
Symptom onset to negative conversion, day, median (IQR)17.0 (13.0–21.0)23.5 (17.8–28.3)32.0 (28.3–43.3)< 0.0010.129
Clinical outcomes
 Mechanical ventilation*36 (21.3)7 (70.0)2 (40.0)0.0020.274
 Days from symptom onset to mechanical ventilation, (IQR)*10.0 (7.0–12.0)6.5 (5.5–8.8)10.5 (9.0–12.0)0.2210.159
 Mortality31 (18.1)4 (40.0)1 (20.0)0.1620.447
 Days from symptom onset to death, median (IQR)15.0 (12.0–21.0)9.0 (3.8–9.0)5.0 (5.0–5.0)0.0320.504

Data shown are number (%) not otherwise specified.

MERS-CoV = Middle East Respiratory Syndrome Coronavirus, SD = standard deviation, DM = diabetes mellitus, NA = not available, BP = blood pressure, WBC = white blood cell, CRP = C-reactive protein, BUN = blood urea nitrogen, CXR = chest X-ray, IQR = interquartile range.

*Data were unavailable in 2 cases (1.1%); †Data were unavailable in 10 cases (5.4%); ‡Data were unavailable in 20 cases (10.8%); §Data were unavailable in 15 cases (8.1%); ∥Data were unavailable in 6 cases (3.2%); ¶Data were unavailable in 43 cases (23.1%).

Data shown are number (%) not otherwise specified. MERS-CoV = Middle East Respiratory Syndrome Coronavirus, SD = standard deviation, DM = diabetes mellitus, NA = not available, BP = blood pressure, WBC = white blood cell, CRP = C-reactive protein, BUN = blood urea nitrogen, CXR = chest X-ray, IQR = interquartile range. *Data were unavailable in 2 cases (1.1%); †Data were unavailable in 10 cases (5.4%); ‡Data were unavailable in 20 cases (10.8%); §Data were unavailable in 15 cases (8.1%); ∥Data were unavailable in 6 cases (3.2%); ¶Data were unavailable in 43 cases (23.1%).

Clinical characteristics

At presentation, patients in the spreader group were more likely than those in the non-spreader group to have a fever of ≥ 38.5°C (40.0% vs. 13.0%, P = 0.009) and a tachypnea of > 24 breaths per minute (33.3% vs. 12.4%, P = 0.034). They were also more likely to have lower respiratory manifestations such as cough, sputum, and dyspnea (86.7% vs. 55.0%, P = 0.031; 73.3% vs. 37.3%, P = 0.011; and 60.0% vs. 18.9%, P = 0.001, respectively). On admission, elevated C-reactive protein (≥ 3.0 mg/dL) was the only laboratory parameter that was more common in the spreader than the non-spreader group (85.7% vs. 43.4%, P = 0.008). Infiltrates involving 3 or more lung zones on chest radiographs taken at presentation were more common in the spreader group than in the non-spreader group (46.7% vs. 10.3%, P < 0.001). The median days from the onset of illness to the negative conversion of sputum MERS-CoV by rRT-PCR were significantly different (27.0 vs. 17.0 days, P < 0.001). Treatment with mechanical ventilation was required in 21.3% (36/169) of the non-spreader group and 60.0% (9/15) of the spreader group (P = 0.002). Deaths occurred in 18.1% (31/171) of the non-spreader group and 33.3% (5/15) of the spreader group (P = 0.162). Median days from symptom onset to death was significantly different (15.0 vs. 9.0 days, P = 0.032). Clinical parameters were not different between super-spreaders and usual-spreaders.

Epidemiologic characteristics

The course of disease spread could not be determined in 10 patients, including 5 with an unidentified source of infection and 5 with more than one possible scenario. Excluding the first imported case, the courses of disease spread could be determined in 175 patients. Of them, 173 were infected at healthcare facilities (12 hospitals, 3 clinics, and 2 ambulances). The disease was transmitted to 2 remaining patients in household settings. The date of symptom onset could not be determined in 5 patients, including 2 patients who were asymptomatic and 3 with an ambiguous onset of MERS-CoV symptoms during another illness. Of the 15 spreaders, 5 and 8 cases were in the second- and third-chain of transmission, respectively (Table 2). Spreaders transmitted MERS-CoV from days 1 to 11 of their illness (median, 7 days; interquartile range [IQR], 5 to 8 days) (Fig. 1A). The number of patients infected by each spreader ranged from 1 to 84 (IQR, 1 to 12).
Table 2

Comparison of epidemiologic characteristics between non-spreaders and spreaders, or usual-spreaders and super-spreaders during the 2015 Korean outbreak of MERS-CoV

Epidemiologic characteristicsNon-spreader (n = 171)Spreader (n = 15)P value
Usual-spreader (n = 10)Super-spreader (n = 5)Non-spreader vs. spreaderUsual-spreader vs. super-spreader
Phase in chain of transmission0.0030.058
 Primary0 (0.0)0 (0.0)1 (20.0)
 Secondary25 (14.6)2 (22.2)3 (60.0)
 Tertiary116 (67.8)7 (77.8)1 (20.0)
 Quaternary23 (13.5)0 (0.0)0 (0.0)
 Undetermined7 (4.1)1 (10.0)0 (0.0)
Symptom onset after June 7*48 (28.9)3 (30.0)0 (0.0)0.4660.999
Median incubation period, day, mean (± SD)7.4 (± 4.5)7.8 (± 2.6)8.0 (± 5.0)0.7160.905
Symptom onset to isolation, day, median (IQR)*2.0 (1.0–6.0)5.0 (3.8–5.8)8.0 (4.0–9.0)0.0570.267
Nonisolated in-hospital days, median (IQR)0.0 (0.0–2.0)2.0 (0.8–4.5)7.0 (4.0–9.0)< 0.0010.061
Nonisolated in-hospital days ≥ 2 day54 (31.6)6 (60.0)5 (100.0)0.0030.999
Symptom onset to diagnosis, day, mean (± SD)*6.5 (± 3.9)7.5 (± 2.6)8.8 (± 3.4)0.1780.400

Data shown are number (%) not otherwise specified.

MERS-CoV = Middle East Respiratory Syndrome Coronavirus, SD = standard deviation, IQR = interquartile range.

*Data were unavailable in 5 cases (2.7%); †Data were unavailable in 7 cases (3.8%).

Fig. 1

Epidemiologic characteristics of 2015 Korean MERS-CoV outbreak. (A) Cumulative number of infected patients according to day of illness of each spreader. When infected patients were exposed to a spreader for more than one day, the number of infected patients was equally divided by the duration (day) of exposure. Different colors denote infections transmitted by different spreaders. Note that the 5 super-spreaders transmitted the virus to 92% (161/175) of all cases. (B) Nonisolated in-hospital days according to the date of symptom onset of each patient. Two spreaders transmitted MERS-CoV to healthcare workers despite the fact that they had been isolated before their symptom onset. (C) Days from symptom onset to diagnosis according to the date of symptom onset of each patient.

MERS-CoV = Middle East Respiratory Syndrome Coronavirus.

Data shown are number (%) not otherwise specified. MERS-CoV = Middle East Respiratory Syndrome Coronavirus, SD = standard deviation, IQR = interquartile range. *Data were unavailable in 5 cases (2.7%); †Data were unavailable in 7 cases (3.8%). Epidemiologic characteristics of 2015 Korean MERS-CoV outbreak. (A) Cumulative number of infected patients according to day of illness of each spreader. When infected patients were exposed to a spreader for more than one day, the number of infected patients was equally divided by the duration (day) of exposure. Different colors denote infections transmitted by different spreaders. Note that the 5 super-spreaders transmitted the virus to 92% (161/175) of all cases. (B) Nonisolated in-hospital days according to the date of symptom onset of each patient. Two spreaders transmitted MERS-CoV to healthcare workers despite the fact that they had been isolated before their symptom onset. (C) Days from symptom onset to diagnosis according to the date of symptom onset of each patient. MERS-CoV = Middle East Respiratory Syndrome Coronavirus. The median duration of incubation was not different between the spreader and non-spreader groups. Median nonisolated in-hospital days were 4 and 0 days in the spreader and non-spreader groups, respectively (IQR, 1 to 7 vs. 0 to 2 days, P < 0.001). Nonisolated in-hospital days were significantly different among the non-spreader, usual-spreader, and super-spreader groups (Fig. 2A). Nonisolated in-hospital days of spreaders were also positively associated with the total number of infected patients, and the number of infected patients per spreader (R2 = 0.520 and 0.625; P = 0.068 and 0.034, respectively) (Fig. 2B).
Fig. 2

Contribution of nonisolated in-hospital days to spreading events. (A) Nonisolated in-hospital days in non-spreader, usual-spreader, and super-spreader groups. Dashed lines denote median values at each group. Data points at 0 are shown at different level for clarity. (B) Number of spreaders (S) and infected patients (I), and I/S ratio according to nonisolated in-hospital days of spreaders. There were positive correlation between nonisolated in-hospital days of spreaders and I (red broken line) or I/S ratio (green broken line).

Contribution of nonisolated in-hospital days to spreading events. (A) Nonisolated in-hospital days in non-spreader, usual-spreader, and super-spreader groups. Dashed lines denote median values at each group. Data points at 0 are shown at different level for clarity. (B) Number of spreaders (S) and infected patients (I), and I/S ratio according to nonisolated in-hospital days of spreaders. There were positive correlation between nonisolated in-hospital days of spreaders and I (red broken line) or I/S ratio (green broken line). Epidemiologic characteristics of super-spreaders and usual-spreaders were not different. However, nonisolated in-hospital days tended to be higher in the super-spreader group (median, 2.0 vs. 7.0 days, P = 0.061). The median number of nonisolated in-hospital days was 1 day in patients who developed symptoms before June 7 and 0 days in patients who developed symptoms after that date (IQR, 0 to 3 vs. 0 to 1 day, P = 0.001) (Fig. 1B, Supplementary Table 1). Days from symptom onset to diagnosis were also significantly different between these groups (mean, 7.5 vs. 4.6, P < 0.001) (Fig. 1C, Supplementary Table 1).

Risk factors for transmission

In multivariate analysis, fever (≥ 38.5°C) (adjusted odds ratio [aOR], 5.54; 95% confidence interval [CI], 1.38–22.30; P = 0.016), chest infiltrates in more than 3 lung zones (aOR, 7.33; 95% CI, 1.93–27.79; P = 0.003), and a longer nonisolated in-hospital day (aOR, 1.32 per 1 day; 95% CI, 1.09–1.60; P = 0.004) were independently associated with the spreader group vs. the non-spreader group (Table 3). Further inclusion of other variables did not result in additional significance.
Table 3

Forward stepwise multivariate analysis for risk factors for transmission of MERS-CoV

VariablesNon-spreader (n = 171)Spreader (n = 15)aOR (95% CI)P value
Fever (≥ 38.5℃)22 (13.0)6 (40.0)5.54 (1.38–22.30)0.016
CXR abnormality in more than 3 lung zones17 (10.3)7 (46.7)7.33 (1.93–27.79)0.003
Nonisolated in-hospital days, median (IQR)0.0 (0.0–2.0)4.0 (1.0–7.0)1.32 (1.09–1.60)0.004

Data shown are number (%).

MERS-CoV = Middle East Respiratory Syndrome Coronavirus, aOR = adjusted odds ratio, CI = confidence interval, CXR = chest X-ray, IQR = interquartile range.

Data shown are number (%). MERS-CoV = Middle East Respiratory Syndrome Coronavirus, aOR = adjusted odds ratio, CI = confidence interval, CXR = chest X-ray, IQR = interquartile range. When we censored the data on symptom onset after June 7 or unknown onset (n = 56), dyspnea (aOR, 4.38; 95% CI, 1.13–16.90; P = 0.032), and a more nonisolated in-hospital days (aOR, 1.31 per 1 day; 95% CI, 1.07–1.60; P = 0.009) were associated with the spreader group (Supplementary Tables 2 and 3). When healthcare workers were censored (n = 39), chest X-ray abnormalities in more than 3 lung zones (aOR, 4.97; 95% CI, 1.28–19.35; P = 0.021), and a more nonisolated in-hospital days (aOR, 5.63 per 1 day; 95% CI, 1.10–28.75; P = 0.038) were associated with the spreader groups (Supplementary Tables 4 and 5).

DISCUSSION

Hospital outbreaks were the defining characteristic of the Korean MERS-CoV outbreak in 2015. In this study, spreaders more frequently had high fever, more extensive infiltrates on chest radiographs, and a longer time to negative conversion of MERS-CoV rRT-PCR than non-spreaders, all suggesting more severe pneumonia. The spreader group had a significantly longer duration of nonisolated in-hospital days than the non-spreader groups. Clinical parameters did not differ between super-spreaders and usual-spreaders, whereas nonisolated in-hospital days were substantially different between these 2 groups. These data suggest that large hospital outbreaks or super-spreading events may not be attributable to clinical manifestations, but to delay in isolation. Spreaders transmitted MERS-CoV between days 1 and 11 of their illness. Of note, even a 1- or 2-day delay in isolating patients led secondary infections, with a peak of cumulative number on the seventh day of illness. These findings imply that MERS-CoV could be transmitted frequently during the early course of the disease. A recent virus shedding study showed that MERS-CoV titers in sputum samples were around 108 copies per milliliter as early as 3 days after symptom onset, while the viral shedding kinetics of the SARS-CoV infection was an inverted V shape, with its sharp peak around day 10 (13). These findings suggest that control of a MERS-CoV outbreak would be more difficult than that of a SARS-CoV outbreak. Considering that the shortest incubation period of MERS-CoV infection is 2 days and that patients may transmit the disease with a high viral load even in the early course of their illness, early detection and isolation of patients is imperative to control an outbreak of MERS-CoV. A standard approach to control an outbreak begins with identifying all exposed individuals and assessing them for close contact, followed by quarantine. However, this approach is labor-intensive and time-consuming, especially when many individuals are exposed. Moreover, identification of all exposed individuals is difficult, because many, such as visitors and family members, may not be registered with hospitals. Indeed, 43.2% of the patients in Korea during the 2015 outbreak had not been identified as exposed individuals and were not monitored (14). Our experience suggests that quarantining all exposed individuals first, followed by an assessment of and monitoring of their close contacts may shorten the delay in isolating MERS patients, especially in healthcare settings. Days of nonisolated in-hospital stay and symptom onset to diagnosis were significantly longer in patients who developed symptoms before June 7 than in patients who did after that date. The last super-spreader developed symptoms on June 5, and no additional super-spreading events occurred after June 7. All advocate the necessity of early adoption of an aggressive isolation policy. Since this was an analysis of a single outbreak, it should be interpreted with caution. Additionally, although we analyzed the severity of symptom or chest infiltrations and time to negative conversion of MERS-CoV rRT-PCR, lack of each patient's serial viral load titers limited a direct evaluation of the degree of viral shedding, which could be another limitation. In conclusion, high fever, more extensive chest infiltrates, and delay in isolation were associated with the transmission of MERS-CoV. Nonisolated in-hospital days were the only parameter that tended to be associated with super-spreaders compared with usual-spreaders. Early active quarantine might help control a future outbreak of MERS.
  10 in total

1.  2014 MERS-CoV outbreak in Jeddah--a link to health care facilities.

Authors:  Ikwo K Oboho; Sara M Tomczyk; Ahmad M Al-Asmari; Ayman A Banjar; Hani Al-Mugti; Muhannad S Aloraini; Khulud Z Alkhaldi; Emad L Almohammadi; Basem M Alraddadi; Susan I Gerber; David L Swerdlow; John T Watson; Tariq A Madani
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

2.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

Authors:  Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  N Engl J Med       Date:  2012-10-17       Impact factor: 91.245

3.  Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015.

Authors: 
Journal:  Osong Public Health Res Perspect       Date:  2015-09-05

4.  Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea.

Authors:  Won Suk Choi; Cheol-In Kang; Yonjae Kim; Jae-Phil Choi; Joon Sung Joh; Hyoung-Shik Shin; Gayeon Kim; Kyong Ran Peck; Doo Ryeon Chung; Hye Ok Kim; Sook Hee Song; Yang Ree Kim; Kyung Mok Sohn; Younghee Jung; Ji Hwan Bang; Nam Joong Kim; Kkot Sil Lee; Hye Won Jeong; Ji-Young Rhee; Eu Suk Kim; Heungjeong Woo; Won Sup Oh; Kyungmin Huh; Young Hyun Lee; Joon Young Song; Jacob Lee; Chang-Seop Lee; Baek-Nam Kim; Young Hwa Choi; Su Jin Jeong; Jin-Soo Lee; Ji Hyun Yoon; Yu Mi Wi; Mi Kyong Joung; Seong Yeon Park; Sun Hee Lee; Sook-In Jung; Shin-Woo Kim; Jae Hoon Lee; Hyuck Lee; Hyun Kyun Ki; Yeon-Sook Kim
Journal:  Infect Chemother       Date:  2016-06-30

5.  The Same Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) yet Different Outbreak Patterns and Public Health Impacts on the Far East Expert Opinion from the Rapid Response Team of the Republic of Korea.

Authors: 
Journal:  Infect Chemother       Date:  2015-12-30

6.  The Korean Middle East Respiratory Syndrome Coronavirus Outbreak and Our Responsibility to the Global Scientific Community.

Authors:  Myoung-Don Oh
Journal:  Infect Chemother       Date:  2016-06-30

7.  Super-spreaders in infectious diseases.

Authors:  Richard A Stein
Journal:  Int J Infect Dis       Date:  2011-07-06       Impact factor: 3.623

8.  MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study.

Authors:  Sun Young Cho; Ji-Man Kang; Young Eun Ha; Ga Eun Park; Ji Yeon Lee; Jae-Hoon Ko; Ji Yong Lee; Jong Min Kim; Cheol-In Kang; Ik Joon Jo; Jae Geum Ryu; Jong Rim Choi; Seonwoo Kim; Hee Jae Huh; Chang-Seok Ki; Eun-Suk Kang; Kyong Ran Peck; Hun-Jong Dhong; Jae-Hoon Song; Doo Ryeon Chung; Yae-Jean Kim
Journal:  Lancet       Date:  2016-07-09       Impact factor: 79.321

9.  Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study.

Authors:  Gerardo Chowell; Fatima Abdirizak; Sunmi Lee; Jonggul Lee; Eunok Jung; Hiroshi Nishiura; Cécile Viboud
Journal:  BMC Med       Date:  2015-09-03       Impact factor: 8.775

10.  Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity.

Authors:  Chan-Ki Min; Shinhye Cheon; Na-Young Ha; Kyung Mok Sohn; Yuri Kim; Abdimadiyeva Aigerim; Hyun Mu Shin; Ji-Yeob Choi; Kyung-Soo Inn; Jin-Hwan Kim; Jae Young Moon; Myung-Sik Choi; Nam-Hyuk Cho; Yeon-Sook Kim
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

  10 in total
  41 in total

1.  Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

Authors:  Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee
Journal:  Antiviral Res       Date:  2017-11-21       Impact factor: 5.970

Review 2.  Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.

Authors:  Reem Hoteit; Hadi M Yassine
Journal:  Vaccines (Basel)       Date:  2022-06-09

3.  Identification of transmission chains and clusters associated with COVID-19 in Tunisia.

Authors:  Mouna Safer; Hejer Letaief; Aicha Hechaichi; Chahida Harizi; Sonia Dhaouadi; Leila Bouabid; Sondes Darouiche; Donia Gharbi; Nawel Elmili; Hamida Ben Salah; Mongi Hammami; Khouloud Talmoudi; Rim Moussa; Nejib Charaa; Hasna Termiz; Fethi Ltaief; Habib Tounekti; Mohamed Makhlouf; Asma Belguith Sriha; Manel Ben Fredj; Sonia Khalfallah; Houcine Jabrane; Selma Mchirgui; Chedli Amich; Radhia Dabghi; Zid Anez; Latifa Abdelkader; Moncef Mhamdi; Nabil Ouerfeli; Salah Zoghlami; Souha Bougatef; Mohamed Kouni Chahed; Nissaf Bouafif Ben Alaya
Journal:  BMC Infect Dis       Date:  2021-05-19       Impact factor: 3.090

4.  The Utility of Preliminary Patient Evaluation in a Febrile Respiratory Infectious Disease Unit outside the Emergency Department.

Authors:  Jun Sik Kang; Byung Woo Jhun; Hee Yoon; Seong Mi Lim; Eunsil Ko; Joo Hyun Park; Sung Yeon Hwang; Se Uk Lee; Tae Rim Lee; Won Chul Cha; Tae Gun Shin; Min Seob Sim; Ik Joon Jo
Journal:  J Korean Med Sci       Date:  2017-09       Impact factor: 2.153

Review 5.  An Opportunistic Pathogen Afforded Ample Opportunities: Middle East Respiratory Syndrome Coronavirus.

Authors:  Ian M Mackay; Katherine E Arden
Journal:  Viruses       Date:  2017-12-02       Impact factor: 5.048

6.  The Impact of Middle East Respiratory Syndrome Outbreak on Trends in Emergency Department Utilization Patterns.

Authors:  So Hyun Paek; Do Kyun Kim; Jin Hee Lee; Young Ho Kwak
Journal:  J Korean Med Sci       Date:  2017-10       Impact factor: 2.153

Review 7.  Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea.

Authors:  Myoung-Don Oh; Wan Beom Park; Sang-Won Park; Pyoeng Gyun Choe; Ji Hwan Bang; Kyoung-Ho Song; Eu Suk Kim; Hong Bin Kim; Nam Joong Kim
Journal:  Korean J Intern Med       Date:  2018-02-27       Impact factor: 2.884

8.  Correlation between Pneumonia Severity and Pulmonary Complications in Middle East Respiratory Syndrome.

Authors:  Wan Beom Park; Kang Il Jun; Gayeon Kim; Jae-Phil Choi; Ji-Young Rhee; Shinhyea Cheon; Chang Hyun Lee; Jun-Sun Park; Yeonjae Kim; Joon-Sung Joh; Bum Sik Chin; Pyeong Gyun Choe; Ji Hwan Bang; Sang-Won Park; Nam Joong Kim; Dong-Gyun Lim; Yeon-Sook Kim; Myoung-Don Oh; Hyoung-Shik Shin
Journal:  J Korean Med Sci       Date:  2018-05-10       Impact factor: 2.153

9.  MERS transmission and risk factors: a systematic review.

Authors:  Ji-Eun Park; Soyoung Jung; Aeran Kim; Ji-Eun Park
Journal:  BMC Public Health       Date:  2018-05-02       Impact factor: 3.295

10.  Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis.

Authors:  Ali Pormohammad; Saied Ghorbani; Alireza Khatami; Rana Farzi; Behzad Baradaran; Diana L Turner; Raymond J Turner; Nathan C Bahr; Juan-Pablo Idrovo
Journal:  Rev Med Virol       Date:  2020-06-05       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.